Not explicitly described in the provided text; financials indicate a research-and-development-focused company (likely life sciences/biotech) primarily funded by grants and equity financings, with significant R&D and G&A expenses and recurring net losses.

# Company Name

Below is a ready-to-fill markdown template for summarizing Item 1. Business from a Form 10-K. Paste the Item 1 text or upload the relevant page and I will complete the template with the exact figures.

- Company overview
  - One- to two-sentence description of what the company does.

- Primary products/services
  - Brief description of core offerings.
  - Key value proposition.

- Markets and customers
  - Target markets (geographic and sector).
  - Number of customers (as reported).
  - Major customer segments or significant customers (if disclosed).

- Operations and scale
  - Number of employees (with as-of date).
  - Locations or facilities (if disclosed).

- Financial highlights
  - Total revenue (period stated).
  - Net income (or loss).
  - Operating income.
  - Other relevant metrics disclosed (e.g., gross profit, EBITDA).

- Business model and strategy
  - Revenue-generation methods, recurring revenue elements, pricing model, distribution channels.

- Other notable disclosures
  - Material dependencies, regulatory considerations, or business risks (as described in Item 1 or related sections).

The company specializes in innovative tech solutions, focusing on enhancing user experience through cutting-edge products and services.

Certainly! Since I don't have access to external databases or specific company details, I'll provide you with a structured markdown template that you can fill in with the specific information about the company. Here's how you can structure the summary:


# Company Overview

## Business Description
The company operates primarily in the [insert industry] sector, focusing on [insert key products/services offered]. With a commitment to [insert mission statement or core values], the company aims to [insert what the company strives to achieve].

## Key Metrics
- **Number of Customers**: [insert number of customers, e.g., "over 5 million"]
- **Number of Employees**: [insert number of employees, e.g., "approximately 10,000"]
- **Total Revenue**: [insert revenue figure, e.g., "$1 billion annually"]
- **Net Income**: [insert income figure, e.g., "$100 million"]

## Market Position
The company is recognized as a leader in [insert market/sector specifics], competing with [insert key competitors]. Its innovative solutions and customer-centric approach have allowed it to capture significant market share.

## Recent Developments
- [Insert any recent news regarding product launches, partnerships, or market expansions]
- [Insert any notable financial achievements, such as revenue growth percentages or profit increases]

## Future Outlook
Looking ahead, the company plans to [insert strategic goals, e.g., expand into new markets, develop new products]. This aligns with its vision of [insert long-term goals or vision statement].

---

*Note: Ensure to update the brackets with accurate and specific details pertaining to the company for a comprehensive overview.*


Feel free to fill in the bracketed sections with data specific to the company you are summarizing, and adjust any of the wording to better fit the narrative you want to convey.

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies that exploit synthetic lethality to target cancer cells with specific genetic vulnerabilities.

### Company Overview: Aprea Therapeutics, Inc.

**Business Focus**  
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of innovative cancer therapies based on the concept of synthetic lethality. The company aims to create drugs that selectively target cancer cells with specific genetic vulnerabilities while sparing normal cells, thereby reducing treatment-related toxicity.

**Core Therapeutic Approach**  
The company specializes in targeting the DNA damage response (DDR) pathways in cancer treatment. Their drug development platform utilizes a discovery approach to identify new cancer targets, focusing on therapies that exploit the vulnerabilities of cancer cells through synthetic lethality. This method involves inhibiting specific genes in support of cancer treatments to enhance efficacy while minimizing adverse effects on healthy cells.

**Product Pipeline**  
Aprea has developed several promising drug candidates:
1. **ATRN-119**: A small molecule inhibitor of ATR (Ataxia Telangiectasia and Rad3-related), currently in a Phase 1/2a clinical trial for patients with advanced solid tumors with mutations in defined DDR-related genes, with an anticipated Phase 1 readout in Q1 2025.
2. **APR-1051**: An inhibitor of WEE1 kinase, with an IND application cleared in March 2024, anticipated to enter Phase 1 clinical trials in the first half of 2024.
3. **Other Discovery Programs**: Includes early-stage programs targeting additional DDR components, currently in lead optimization.

**Employees**  
As of December 31, 2023, Aprea Therapeutics has **7 full-time employees**. The workforce primarily consists of employees engaged in research and development, with management and operational support staff fulfilling additional roles.

**Financials**  
- **Revenue**: Aprea Therapeutics has not generated any commercial revenue to date.
- **Income**: The company has incurred significant net losses, with financial results showing a net loss of **$14.3 million** for the year ended December 31, 2023, and an accumulated deficit of **$308.1 million** as of the same date.
- The company has financed its operations through capital raised via **private placements of preferred stock** and initial public offerings, while it is yet to achieve profitability.

**Customer Base**  
Aprea Therapeutics is involved in clinical trials primarily targeting oncologists, cancer treatment facilities, and research institutions. As such, while the company does not have a traditional end-customer sales structure at this stage, its ultimate customers will be healthcare providers, patients, and payors involved in cancer therapeutics.

**Strategic Goals**  
Aprea aims to:

- Advance the clinical development of its lead product candidates and explore additional indications.
- Establish a robust pipeline of therapies leveraging synthetic lethality to target cancer more effectively.
- Attain regulatory approvals for its drug candidates to commercialize them, eventually leading to revenue generation.

In summary, Aprea Therapeutics, Inc. is at the forefront of pioneering cancer therapies, focusing on harnessing synthetic lethality for effective treatment while navigating the complexities of drug development and regulatory approvals.

Aprea Therapeutics, Inc.

10-K / March 16, 2026

10-K / March 25, 2025

10-K / March 26, 2024

10-K / March 16, 2026

Company Name